Gene therapy, CRISPR, synthetic biology, and emerging platforms—what's real, what's hype, and what translates.
Sidewinder Therapeutics and Stipple Bio have each secured significant financing to enhance antibody drug conjugate therapies for cancer treatment, aiming to improve targeting and clinical outcomes.
Sidewinder Therapeutics and Stipple Bio have each secured significant financing to enhance antibody drug conjugate therapies for cancer treatment, aiming to improve targeting and clinical outcomes.
READ MORE
Oricell Therapeutics has raised $110 million in funding to develop a novel CAR-T cell therapy targeting GPC3, a protein highly expressed in liver cancer, breaking ground in a field with no FDA-approved treatments for this target.
CAR-T cell therapies are showing sustained promise in inducing remissions in autoimmune diseases five years after their initial breakthrough in lupus treatment.
Recent insights suggest that genetic variations may slightly influence patient responses to GLP-1 receptor agonist therapies for weight loss and metabolic conditions.
Novo Nordisk has introduced a high-dose version of Wegovy, an obesity drug that continues to shape treatment paradigms in metabolic health, advancing options for patients and impacting the competitive landscape in biotech and healthcare.
Pinnacle Medicines secured $89 million to advance their development of oral peptide drugs that aim to deliver the efficacy of injectable biologics with the convenience of oral dosing, focusing on treatments for asthma, COPD, and immunological disorders.
Ambrosia Biosciences has secured $100 million in Series B funding to develop next-generation small-molecule GLP-1 receptor agonists, representing a novel approach distinct from the current peptide-dominant therapies.
Alumis is leveraging genomic research to develop envudeucitinib, a TYK2 inhibitor considered best in class, targeting autoimmune diseases like plaque psoriasis with precision immunology.
Allogene Therapeutics is nearing a pivotal readout for its off-the-shelf CAR-T therapy, potentially validating a new era in cell and gene therapy manufacturing with broad implications across the biopharma industry.
Structure Therapeutics has made headlines with significant weight loss outcomes in a mid-stage trial of its experimental GLP-1 obesity pill, aleniglipron. Plans for a Phase 3 study are underway as the company advances its development pipeline.
Recent research has uncovered that cancer cells can present certain proteins on their surface, potentially creating novel targets for immunotherapy against solid tumors.
